|  |  |
| --- | --- |
|  | |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4818** |
| Title of the Manuscript: | **Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer** |
| Type of the Article | **Book Chapter** |

**Special note:**

**A research paper already published in a journal can be published as a Book Chapter in an expanded form with proper copyright approval.**

**Source Article:**

**This chapter is an extended version of the article published by the same author(s) in the following journal.**

**Cancer Control, 31: 1-18, 2024.**

**DOI:** [**https://doi.org/10.1177/10732748241302863**](https://doi.org/10.1177/10732748241302863)

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment **Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **This paper gives an in-depth summary of chemopreventive approaches specifically directed at men with localized prostate cancer who are treated on active surveillance. Its usefulness is in looking at both established agents (like 5-alpha reductase inhibitors, lycopene, selenium, vitamin E, green tea catechins) and newer research directions. By integrating mechanistic findings, early-phase trial results, and the gaps that remain in the existing literature, this chapter elucidates key steps to move chemoprevention research into large-scale clinical trials. Finally, it emphasizes how organized and evidence-based clinical trials can prevent overtreatment morbidities in men with low-grade or localized disease and improve outcomes.** |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | **Yes, the current title, "Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer," does indeed capture well the focus of the chapter. It explicitly mentions the emphasis on chemoprevention in a very narrow population—men with localized prostate cancer. Nothing needs to be changed in the title.** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **The abstract is well written, giving a summary of prostate cancer epidemiology, justification for active surveillance, and a reason why chemoprevention is appealing. Add a brief remark on how the field can advance to well-powered phase III trials, to impart the abstract a sense of foresight. Other than that, it is to the point and presents the essence well.** |  |
| **Is the manuscript scientifically, correct? Please write here.** | * **The paper is scientifically rigorous, based on current knowledge regarding prostate cancer epidemiology and the chemistry of chemoprevention. It integrates preclinical rationale, mechanistic targets, and early-phase trials, which enhances scientific rigor.** * **It also accurately identifies the heterogeneity of prostate cancer and highlights the need for strong clinical trial design, including well-validated biomarkers (e.g., Ki-67, PSA kinetics, MRI results, etc.).** * **Generally, the scientific explanations and interpretations look correct and based on current literature.** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.**  **-** | **The references are broad and include key trials, like SELECT and the large 5-alpha reductense inhibitor trials, among others. They comprise both older, seminal studies and newer data essential to understanding present limitations and future directions.** |  |
| Is the language/English quality of the article suitable for scholarly communications? | The language is clear, well-organized, and suitable for an academic audience. Appropriate terminology specific to prostate cancer screening and chemoprevention is employed, making the content readable but comprehensive. |  |
| Optional/General comments |  |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in detail)* |  |

**Reviewer details:**

**Susmita Chakrabarty, DRIEMS University, India**